However, combination treatment with MEK and SHP2 inhibitors resulted in the continued regression of tumor growth in xenograft models of pancreatic cancer and NSCLC derived from patients, indicating the clinical efficacy of dual SHP2/MEK inhibition for KRAS-mutant cancers (85). The gene discussed is KRAS; the disease is familial pancreatic carcinoma.